Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05483933 | Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers | PHASE1 | COMPLETED | 86 | — | — | Aug 18, 2022 | Feb 7, 2025 | Dec 23, 2025 | 21 | United States, Canada +2 |
Number of participants with treatment emergent adverse events from dose escalation and expansion cohorts
Based on review of all data, including safety, tolerability, PK, antitumor activity, and PD effects"
| Arm | Type | Description |
|---|---|---|
| Pegylated Liposomal Doxorubicin + SL-172154 (SIRPα-Fc-CD40L) | EXPERIMENTAL | Pegylated Liposomal Doxorubicin (PLD) will be administered via intravenous administration + SL-172154 (SIRPα-Fc-CD40L) will be administered via intravenous administration. |
| Mirvetuximab + SL-172154 (SIRPα-Fc-CD40L) | EXPERIMENTAL | Mirvetuximab (MIRV) will be administered via intravenous administration + SL-172154 (SIRPα-Fc-CD40L) will be administered via intravenous administration |
| Name | Type | Description |
|---|---|---|
| Pegylated Liposomal Doxorubicin + SL-172154 | DRUG | The investigational product, SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc. |
| Mirvetuximab + SL-172154 | DRUG | The investigational product, SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc. |
Inclusion Criteria: 1. Subject has voluntarily agreed to participate by giving written informed consent in accordance with ICH/GCP guidelines and applicable local regulations. 2. Age ≥18 years 3. \[PLD Cohort\] Subject has a histologically confirmed diagnosis of high grade epithelial ovarian cancer...